542 related articles for article (PubMed ID: 24641480)
41. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
42. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome.
Graham SJ; Sharpe RW; Steinberg SM; Cotelingam JD; Sausville EA; Foss FM
Cancer; 1993 Aug; 72(3):726-34. PubMed ID: 8334625
[TBL] [Abstract][Full Text] [Related]
43. Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides.
Tosca A; Linardopoulos S; Malliri A; Hatziolou E; Nicolaidou A; Spandidos DA
Anticancer Res; 1991; 11(4):1433-8. PubMed ID: 1746900
[TBL] [Abstract][Full Text] [Related]
44. Clinical staging for cutaneous T-cell lymphoma.
Lamberg SI; Green SB; Byar DP; Block JB; Clendenning WE; Douglas MC; Epstein EH; Fuks ZY; Golitz LE; Lorincz AL
Ann Intern Med; 1984 Feb; 100(2):187-92. PubMed ID: 6607008
[TBL] [Abstract][Full Text] [Related]
45. Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides.
Boonk SE; Putter H; Koolhof L; Willemze R; Vermeer MH
Br J Dermatol; 2014 May; 170(5):1080-6. PubMed ID: 24299563
[TBL] [Abstract][Full Text] [Related]
46. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement.
Hodak E; Amitay-Laish I; Feinmesser M; Davidovici B; David M; Zvulunov A; Pavlotsky F; Yaniv I; Avrahami G; Ben-Amitai D
J Am Acad Dermatol; 2014 Jun; 70(6):993-1001. PubMed ID: 24629999
[TBL] [Abstract][Full Text] [Related]
47. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
48. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
Sentis HJ; Willemze R; Scheffer E
J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
[TBL] [Abstract][Full Text] [Related]
49. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
50. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
51. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.
Klein RS; Dunlop JD; Samimi SS; Morrissey KA; Evans KG; Gardner JM; Introcaso CE; Vittorio CC; Rook AH; Micaily B; Kim EJ
J Am Acad Dermatol; 2013 Jun; 68(6):972-7. PubMed ID: 23415461
[TBL] [Abstract][Full Text] [Related]
52. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
Olsen E; Vonderheid E; Pimpinelli N; Willemze R; Kim Y; Knobler R; Zackheim H; Duvic M; Estrach T; Lamberg S; Wood G; Dummer R; Ranki A; Burg G; Heald P; Pittelkow M; Bernengo MG; Sterry W; Laroche L; Trautinger F; Whittaker S;
Blood; 2007 Sep; 110(6):1713-22. PubMed ID: 17540844
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.
Moriarty B; Whittaker S
Expert Rev Hematol; 2015 Apr; 8(2):159-71. PubMed ID: 25495961
[TBL] [Abstract][Full Text] [Related]
54. Does the new staging system proposed for mycosis fungoides and Sézary syndrome provide reliable agreement for T1 and T2 disease?
Fernández-de-Misa R; Hernández Machín B; Aguirre-Jaime A; Pérez-Méndez LI; Peñate Y; Suárez Hernández J
Dermatology; 2015; 230(1):40-5. PubMed ID: 25471055
[TBL] [Abstract][Full Text] [Related]
55. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
Toro JR; Stoll HL; Stomper PC; Oseroff AR
J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
[TBL] [Abstract][Full Text] [Related]
56. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Dmitrovsky E; Matthews MJ; Bunn PA; Schechter GP; Makuch RW; Winkler CF; Eddy J; Sausville EA; Ihde DC
J Clin Oncol; 1987 Feb; 5(2):208-15. PubMed ID: 3492594
[TBL] [Abstract][Full Text] [Related]
57. Mycosis fungoides: classic disease and variant presentations.
Howard MS; Smoller BR
Semin Cutan Med Surg; 2000 Jun; 19(2):91-9. PubMed ID: 10892710
[TBL] [Abstract][Full Text] [Related]
58. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
59. Mycosis fungoides.
Zinzani PL; Ferreri AJ; Cerroni L
Crit Rev Oncol Hematol; 2008 Feb; 65(2):172-82. PubMed ID: 17950613
[TBL] [Abstract][Full Text] [Related]
60. [Prognosis of primary cutaneous lymphomas].
Grange F; Bagot M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
